Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Subsite-specific association of DEAD box RNA helicase DDX60 with the development and prognosis of oral squamous cell carcinoma.

Fu TY, Wu CN, Sie HC, Cheng JT, Lin YS, Liou HH, Tseng YK, Shu CW, Tsai KW, Yen LM, Tseng HW, Tseng CJ, Ger LP, Liu PF.

Oncotarget. 2016 Dec 20;7(51):85097-85108. doi: 10.18632/oncotarget.13197.

2.

Coordination of signalling networks and tumorigenic properties by ABL in glioblastoma cells.

Lamballe F, Toscano S, Conti F, Arechederra M, Baeza N, Figarella-Branger D, Helmbacher F, Maina F.

Oncotarget. 2016 Nov 15;7(46):74747-74767. doi: 10.18632/oncotarget.12546.

3.

Molecular mechanisms of the effect of TGF-β1 on U87 human glioblastoma cells.

Bryukhovetskiy I, Shevchenko V.

Oncol Lett. 2016 Aug;12(2):1581-1590. Epub 2016 Jun 22.

4.

Resveratrol directly targets DDX5 resulting in suppression of the mTORC1 pathway in prostate cancer.

Taniguchi T, Iizumi Y, Watanabe M, Masuda M, Morita M, Aono Y, Toriyama S, Oishi M, Goi W, Sakai T.

Cell Death Dis. 2016 May 5;7:e2211. doi: 10.1038/cddis.2016.114.

5.

SHP-2-upregulated ZEB1 is important for PDGFRα-driven glioma epithelial-mesenchymal transition and invasion in mice and humans.

Zhang L, Zhang W, Li Y, Alvarez A, Li Z, Wang Y, Song L, Lv D, Nakano I, Hu B, Cheng SY, Feng H.

Oncogene. 2016 Oct 27;35(43):5641-5652. doi: 10.1038/onc.2016.100. Epub 2016 Apr 4.

6.

Activation of the TGFβ pathway impairs endothelial to haematopoietic transition.

Vargel Ö, Zhang Y, Kosim K, Ganter K, Foehr S, Mardenborough Y, Shvartsman M, Enright AJ, Krijgsveld J, Lancrin C.

Sci Rep. 2016 Feb 19;6:21518. doi: 10.1038/srep21518.

7.

PDGF-dependent β-catenin activation is associated with abnormal pulmonary artery smooth muscle cell proliferation in pulmonary arterial hypertension.

Takahashi J, Orcholski M, Yuan K, de Jesus Perez V.

FEBS Lett. 2016 Jan;590(1):101-9. doi: 10.1002/1873-3468.12038. Epub 2016 Jan 8.

8.

DDX3, a potential target for cancer treatment.

Bol GM, Xie M, Raman V.

Mol Cancer. 2015 Nov 5;14:188. doi: 10.1186/s12943-015-0461-7. Review.

9.

AIF inhibits tumor metastasis by protecting PTEN from oxidation.

Shen SM, Guo M, Xiong Z, Yu Y, Zhao XY, Zhang FF, Chen GQ.

EMBO Rep. 2015 Nov;16(11):1563-80. doi: 10.15252/embr.201540536. Epub 2015 Sep 28.

10.

Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer.

Heerma van Voss MR, Vesuna F, Trumpi K, Brilliant J, Berlinicke C, de Leng W, Kranenburg O, Offerhaus GJ, Bürger H, van der Wall E, van Diest PJ, Raman V.

Oncotarget. 2015 Sep 29;6(29):28312-26. doi: 10.18632/oncotarget.4873.

11.

DDX5 promotes proliferation and tumorigenesis of non-small-cell lung cancer cells by activating β-catenin signaling pathway.

Wang Z, Luo Z, Zhou L, Li X, Jiang T, Fu E.

Cancer Sci. 2015 Oct;106(10):1303-12. doi: 10.1111/cas.12755. Epub 2015 Sep 3.

12.

Combined inhibition of EGFR and c-ABL suppresses the growth of triple-negative breast cancer growth through inhibition of HOTAIR.

Wang YL, Overstreet AM, Chen MS, Wang J, Zhao HJ, Ho PC, Smith M, Wang SC.

Oncotarget. 2015 May 10;6(13):11150-61.

13.

Crosstalk between Wnt/β-catenin and Hedgehog/Gli signaling pathways in colon cancer and implications for therapy.

Song L, Li ZY, Liu WP, Zhao MR.

Cancer Biol Ther. 2015;16(1):1-7. doi: 10.4161/15384047.2014.972215. Review.

14.

Signaling-mediated regulation of MicroRNA processing.

Shen J, Hung MC.

Cancer Res. 2015 Mar 1;75(5):783-91. doi: 10.1158/0008-5472.CAN-14-2568. Epub 2015 Feb 6. Review.

15.

Transglutaminase 2 promotes PDGF-mediated activation of PDGFR/Akt1 and β-catenin signaling in vascular smooth muscle cells and supports neointima formation.

Nurminskaya M, Beazley KE, Smith EP, Belkin AM.

J Vasc Res. 2014;51(6):418-28. doi: 10.1159/000369461. Epub 2015 Jan 22.

16.

DEAD-box protein p68 is regulated by β-catenin/transcription factor 4 to maintain a positive feedback loop in control of breast cancer progression.

Guturi KK, Sarkar M, Bhowmik A, Das N, Ghosh MK.

Breast Cancer Res. 2014 Dec 12;16(6):496. doi: 10.1186/s13058-014-0496-5.

17.

P68 RNA helicase as a molecular target for cancer therapy.

Dai TY, Cao L, Yang ZC, Li YS, Tan L, Ran XZ, Shi CM.

J Exp Clin Cancer Res. 2014 Aug 24;33:64. doi: 10.1186/s13046-014-0064-y. Review.

18.

The synergistic in vitro and in vivo antitumor effect of combination therapy with salinomycin and 5-fluorouracil against hepatocellular carcinoma.

Wang F, Dai W, Wang Y, Shen M, Chen K, Cheng P, Zhang Y, Wang C, Li J, Zheng Y, Lu J, Yang J, Zhu R, Zhang H, Zhou Y, Xu L, Guo C.

PLoS One. 2014 May 9;9(5):e97414. doi: 10.1371/journal.pone.0097414. eCollection 2014.

19.

Molecular mechanisms of epithelial-mesenchymal transition.

Lamouille S, Xu J, Derynck R.

Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96. doi: 10.1038/nrm3758. Review.

20.

A Distinct Slow-Cycling Cancer Stem-like Subpopulation of Pancreatic Adenocarcinoma Cells is maintained in Vivo.

Dembinski JL, Krauss S.

Cancers (Basel). 2010 Nov 29;2(4):2011-25. doi: 10.3390/cancers2042011.

Supplemental Content

Support Center